Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors

N/ACompletedNCT05168631

Latin American Cooperative Oncology Group88 enrolled

Overview

Multicenter retrospective longitudinal analytical study of patients with neuroendocrine tumors.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neuroendocrine Tumors Carcinoma;Endocrine

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 18 years or older and with histologically confirmed neuroendocrine tumors; * Metastatic or inoperable disease; * Patients with clinical information about the therapies received, including exclusive palliative care. Exclusion Criteria: * Lack of data on survival outcomes and/or details on treatments received.

Locations (8)

Hospital de Gastroenterología Carlos Bonorino Udaondo

Buenos Aires, Buenos Aires, Argentina

Instituto Alexander Fleming

Buenos Aires, Buenos Aires, Argentina

Universidade Federal do Ceará/HOSPITAL UNIVERSITARIO WALTER CANTIDIO

Fortaleza, Ceará, Brazil

Ensino E Terapia de Inovacao Clinica Amo - Etica

Outcomes

Primary Outcomes

Overall survival

Time frame: 2022

Secondary Outcomes

Response rate per RECIST 1.1;

Time frame: 2022

Progression-free survival by RECIST 1.1 from D1 of each treatment;

Time frame: 2022

Symptom control time

Improvement of symptoms and/or stabilization of radiological disease in non-functioning ENT, at the physician's discretion

Time frame: 2022

Incidence of complications of the disease and/or treatments, defined by adverse events

Time frame: 2022

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.